新冠口服藥療效顯著兼美日放寬入境 首都機場/南航/國航漲9.5%-11% 國泰創逾七個月高
默克(MRK.US)後,美國再有藥廠輝瑞(PFE.US)上周五發布新冠口服藥臨床試驗中期結果顯示能夠將患者住院和死亡風險大減八成九,刺激該股上周五急漲近11%收48.61美元。此外,美國本周一起放寬包括中國、印度及歐洲等33國已接種新冠疫苗的旅客入境免隔離限制,旅遊相關板塊應聲炒起,其中美國航空(AAL.US)、聯合航空(UAL.US)、達美航空(DAL.US)、挪威郵輪(NCLH.US)、嘉年華郵輪(CCL.US)及皇家加勒比郵輪(RCL.US)漲近6%-9%。
日本今天(8日)起也放寬已完成接種兩劑新冠疫苗的非旅遊目的海外人士入境限制。此外,本港特首林鄭月娥接受《經濟日報》訪問時表示,本港要爭取與內地盡快通關,但不能要求內地大規模開放所有省市讓港人免檢疫進入,必須小規模、有序及逐步通關,預料通關初期只限廣東省地區,香港與深圳接壤的陸路口岸或港珠澳大橋可能是首批開放的口岸。
中港航空股今天逆市全面抽升,國航(00753.HK)及南航(01055.HK)扭五連跌,股價高見5.83元(暫受制牛熊線5.88元)及5.2元,現報5.79元及4.91元,急漲11%及10%,前者股價一舉升破四條移動平均線,後者股價一舉重越5條移動平均線(牛熊線為4.87元),成交急增至4,432萬及3,989萬股。國航A(601111.SH)及南航A(600029.SH)漲8%及7%,曾漲停分別高見9.14元人民幣及7.08元人民幣。
東航(00670.HK)扭五連跌,股價重越4條移動平均線(百天線為3.05元),高見3.13元,現報3.05元,升7%,成交增至1,910萬股;東航A(600115.SH)曾漲逾7%高見5.12元人民幣,現報4.91元人民幣,漲2.7%。
首都機場(00694.HK)扭兩連跌,股價重越20天及10天線,最高見5.34元,現報5.31元,急漲9.5%,成交增至1,361萬股;美蘭空港(00357.HK)扭三連跌,股價由兩個月低位回升,最高見28.35元(暫受制百天線28.9元),現報27.5元,回升4.4%。
國泰(00293.HK)突破上月中旬所造高位7.43元,最高見7.6元,創逾七個月高,現報7.49元,續升4.6%,成交急增至1,263萬股。
其他旅遊相關股也藉勢舞起,復星旅遊文化(01992.HK)突破5條移動平均線(牛熊線為10元),最高見11.42元,現報10.98元,急漲13%。新秀麗(01910.HK)扭五連跌,股價急漲15%報18.4元即市高位,成交急增至1,036萬股。醫美股卓珈控股(01827.HK)突破10天及20天線,最高見1.89元,現報1.86元,急漲18%。嘉年華國際(00996.HK)高見0.107元,現報0.103元,漲23%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.